Harbourvest Partners’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Harbourvest Partners’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-56,979	Closed	-$1.28M	–	63
2023 Q2	$1.28M	Sell	56,979 -1	-0%	-$7	0.36%	34
2023 Q1	$689K	Hold	56,980	–	–	0.23%	40
2022 Q4	$259K	Hold	56,980	–	–	0.09%	49
2022 Q3	$374K	Hold	56,980	–	–	0.12%	51
2022 Q2	$615K	Hold	56,980	–	–	0.2%	43
2022 Q1	$1.09M	Hold	56,980	–	–	0.22%	44
2021 Q4	$2.04M	Hold	56,980	–	–	0.26%	33
2021 Q3	$4.18M	Hold	56,980	–	–	0.39%	20
2021 Q2	$7.95M	Hold	56,980	–	–	0.76%	15
2021 Q1	$16.6M	Hold	56,980	–	–	2.22%	6
2020 Q4	$35.6M	Buy	+56,980	New	+$25.9M	13.9%	3

Other funds holding SGTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Harbourvest Partners's SGTX Position: Q3 2023 in Review

Harbourvest Partners sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2023, closing a stake of 56,979 shares — an estimated $1.28M sold.

Harbourvest Partners first reported a position in SGTX in Q4 2020 and held it in 11 quarters. The position peaked at $35.6M in Q4 2020. 1 fund tracked by Wall St. Rank holds SGTX as of Q3 2023.

Harbourvest Partners reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Harbourvest Partners sold 56,979 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.28M.
Harbourvest Partners first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Harbourvest Partners's Sigilon Therapeutics, Inc. Common Stock position peaked at $35.6M in Q4 2020.
1 fund tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Harbourvest Partners's 13F filing for Q3 2023, filed 14 Nov 2023.